Biotech giant CSL tumbles despite 20pc profit growth led by core immunoglobulins business

by Pelican Press
24 views 0 minutes read

Biotech giant CSL tumbles despite 20pc profit growth led by core immunoglobulins business

CSL is forecasting double-digit earnings growth this year underpinned by its key immunoglobulins franchise but the biotech giant warned revenue growth will be on the lower end.


Source link

#Biotech #giant #CSL #tumbles #20pc #profit #growth #led #core #immunoglobulins #business

You may also like